The size of the Migraine Drug Market in North America is valued at USD 1.50 billion in 2022. This value is estimated to be growing at a CAGR of 3.98% to reach USD 1.82 billion by 2027.
Growing awareness of mental health disorders such as depression and stress is expected to boost the Migraine drug market growth in North America. Social elements such as economic stress, the partition of family-oriented supporting structures, exacerbating environmental conditions are further estimated to escalate the market growth during the review period. Increasing the necessity for migraine drugs, the attainability of research funds from private and public organizations, enhancement of reimbursement scenarios towards related medications is to propel the market growth. The invention of novel drugs and results related to the quick obtainment of new medicines is to surge the market growth during the assessment period. The rising attention of vendors on the developing markets is to fuel the market.
Side-effects related to the usage of migraine drugs and lack of awareness in people regarding migraine drugs, particularly in women, are expected to hinder the market. Lengthy and time-consuming FDA approval process for migraine drugs and the shortage of neurosurgeons and physicians are significant restraints for the market growth.
This research report on the North America Migraine Drugs Market has been segmented and sub-segmented into the following categories:
Regionally, the North America migraine drug market was the dominating region in the global market in 2019. It is predicted that North American will be continuing its dominance between 2020 to 2025. According to the American Migraine Association, over 36 million people had migraines in 2015.
The migraine drug market in the United States is expected to dominate the North American market during the forecast period and held 65% of the share in 2017. The introduction of Calcitonin gene-related (CGRP) based therapies, growing acquisition of new treatments, and large aided population are expected to drive the market in the United States. Increasing intake of unhealthy food and increasing incidence of chronic diseases, presence of key players, and escalating concentration on precision medicine in the United States are further estimated to favor the market to grow in the forecast timeframe.
The Canadian market is expected to showcase a promising CAGR due to the increasing prevalence of migraine
Companies playing a dominant role in the North America Migraine Drug Market profiled in this report are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories. The other prominent vendors the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories, OptiNose, Pfizer, Pozen, Eisai, Raptor, RedHill, SUDA, Teva, Aegis Therapeutics, Merck, TG Therapeutics, NValeant, Winston Pharmaceuticals, Allergan, and Zogenix.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Introduction
5.1.2 Preventive
5.1.3 Abortive
5.1.4 Y-o-Y Growth Analysis, By Treatment
5.1.5 Market Attractiveness Analysis, By Treatment
5.1.6 Market Share Analysis, By Treatment
5.2 Therapeutic
5.2.1 Introduction
5.2.2 Triptents
5.2.3 Ergots
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By Therapeutic
5.2.6 Market Attractiveness Analysis, By Therapeutic
5.2.7 Market Share Analysis, By Therapeutic
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment
6.1.3.3 By Therapeutic
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment
6.1.4.3 By Therapeutic
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment
6.1.5.3 By Therapeutic
6.2 United States
6.3 Canada
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Allergan
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Endo International
8.3 GlaxoSmithKline
8.4 Impax
8.5 Pfizer
8.6 Aegis Therapeutics
8.7 Alder Biopharmaceuticals
8.8 Astellas
8.9 AstraZeneca
8.10 Aeriel BioPharma
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
